Beigene Ltd at Morgan Stanley Global Healthcare Conference (Virtual) Transcript
Good morning, everybody, again. Thanks for joining us for the next session. I'm Matthew Harrison, one of the biotech analysts here at Morgan Stanley. Very pleased to have BeiGene with me to start off this session.
Briefly before we get started, I need to read a disclosure statement. Please note that this webcast is for Morgan Stanley's clients and appropriate Morgan Stanley employees only. This webcast is not for members of the press. If you are a member of the press, please disconnect and reach out separately. For important disclosures, please see the Morgan Stanley research disclosure website at morganstanley.com/researchdisclosures. And if you have any questions, please reach out to your Morgan Stanley sales representative.
With that, very pleased to have John Oyler, the CEO; and Howard Liang, who is the CFO at BeiGene. And John, I thought maybe to start us off over the course of the last, I guess, it's 12 months or so, you've had some pretty sizable partnerships, including the Amgen partnership. And I
Access to All Earning Calls and Stock Analysis | |
30-Year Financial on one screen | |
All-in-one Stock Screener with unlimited filters | |
Customizable Stock Dashboard | |
Real Time Insider Trading Transactions | |
8,000+ Institutional investors’ 13F holdings | |
Powerful Excel Add-in and Google sheets Add-on | |
All data downloadable | |
Quick customer support | |
And much more... |